APLS Logo

Apellis Pharmaceuticals, Inc. (APLS) 

NASDAQ
Market Cap
$3.45B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
440 of 776
Rank in Industry
229 of 433

Largest Insider Buys in Sector

APLS Stock Price History Chart

APLS Stock Performance

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment …

Insider Activity of Apellis Pharmaceuticals, Inc.

Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $51M worth of Apellis Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $30.16M and sold $37.27M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.

List of Insider Buy and Sell Transactions, Apellis Pharmaceuticals, Inc.

2024-09-16Saledirector
37,000
0.0303%
$36.23$1.34M-23.02%
2024-09-16SaleVP/Chief Accounting Officer
192
0.0002%
$36.21$6,952-23.02%
2024-09-03SaleVP/Chief Accounting Officer
550
0.0005%
$39.49$21,720-27.68%
2024-06-21Saledirector
37,000
0.028%
$39.24$1.45M-3.97%
2024-05-08SaleChief Scientific Officer
78,907
0.0651%
$42.35$3.34M-8.27%
2024-04-08SaleChief Scientific Officer
69,107
0.0577%
$54.17$3.74M-26.26%
2024-04-01SaleChief Financial Officer
4,000
0.0033%
$58.66$234,640-33.38%
2024-03-19Saledirector
18,681
0.0156%
$57.18$1.07M-29.70%
2024-03-18SaleChief Business & Strat Officer
9,913
0.0083%
$56.90$564,050-28.76%
2024-03-15SaleVP/Chief Accounting Officer
184
0.0002%
$56.46$10,389-29.38%
2024-03-13SaleChief Technical Officer
11,220
0.0094%
$57.56$645,838-30.09%
2024-03-08SaleChief Scientific Officer
69,107
0.0574%
$62.19$4.3M-34.52%
2024-03-01SaleChief Executive Officer
250,000
0.2068%
$64.11$16.03M-36.76%
2024-03-01SaleChief Financial Officer
6,000
0.0049%
$63.22$379,340-36.76%
2024-02-12SaleChief Scientific Officer
1,148
0.001%
$67.77$77,796-39.32%
2024-02-12SaleChief Executive Officer
3,962
0.0034%
$67.77$268,492-39.32%
2024-02-12SaleGeneral Counsel
781
0.0007%
$67.77$52,926-39.32%
2024-02-12SaleChief Financial Officer
1,431
0.0012%
$67.77$96,974-39.32%
2024-02-12SaleChief Commercial Officer
1,148
0.001%
$67.77$77,796-39.32%
2024-02-12SaleChief Business & Strat Officer
597
0.0005%
$67.77$40,457-39.32%

Insider Historical Profitability

10.88%
Sullivan Timothy EugeneChief Financial Officer
93338
0.0767%
$28.33110+1.94%
SCHEIBLER LUKASChief Research Officer
68299
0.0561%
$28.33112<0.0001%
Morningside Venture Investments Ltd10 percent owner
12806342
10.5172%
$28.3390+6.91%
venBio Global Strategic Fund II L.P.10 percent owner
3579305
2.9395%
$28.3310+31.35%
Hillhouse Capital Management, Ltd.10 percent owner
3527152
2.8967%
$28.3310+31.35%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Wellington Management Company$885.11M12.4115.06M-8.44%-$81.54M0.15
Ecor1 Capital Llc$667.59M9.3611.36M+1.65%+$10.84M4.68
Avoro Capital Advisors Llc$653.11M9.1511.11M0%+$07.83
The Vanguard Group$558.75M7.839.51M-0.52%-$2.93M0.01
BlackRock$322.97M4.535.49M+2.11%+$6.66M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.